Newsletters

[Nature Communications] Investigators examined the role of the transcriptional factor GFI1B and its co-factor LSD1/KDM1A in endothelial- to-hematopoietic transition.

[Nature Communications] The authors uncovered the role of the angioneurin fibronectin leucine rich transmembrane protein (FLRT) 2 in central nervous system vascular development in the mouse.

[Trends in Molecular Medicine] Scientists compile the current understanding of the intricate relationship between various RNA modifications and angiogenic mechanisms, spotlighting emerging evidence that underscore their pivotal regulatory roles in both physiological and pathological angiogenesis.

[UBC Faculty of Medicine] Twenty-eight projects led by Faculty of Medicine researchers, including Dr. Liam Brunham, have received new funding from Michael Smith Health Research BC through the 2024 Convening & Collaborating and Reach programs. Dr. Brunham will be studying genetic lipid disorders and premature atherosclerotic cardiovascular disease.

[Frontiers In Immunology] The authors discuss the mechanical properties of tumors, the impact of a stiff tumor microenvironment on tumor cells and immune cells, and the strategies to modulate tumor mechanics.

[Advanced Biology] Researchers investigated the role of pathogenic ECM remodeling in the age-related deterioration and fibrogenic conversion of muscle stem cells.

[BMJ Open] Researchers established an innovative and effective method to generate corneal stromal keratocytes via the embryoid body-based differentiation of human iPSCs, which may be employed for cell-based therapy of corneal stromal opacities.

[Signal Transduction and Targeted Therapy] The authors devised a screening system using primary human hematopoietic stem and progenitor cells. They discovered that BRAF inhibitors, commonly used to treat BRAFV600E melanoma, could effectively promote progenitor cell proliferation by temporarily delaying erythroid differentiation.

[Nature Communications] Scientists found that the membrane glycoprotein dysadherin directly targeted matrix metalloprotease 9 (MMP9), initiating ECM remodeling within the tumor microenvironment and amplifying cancer progression.

[Haematologica] The authors modeled loss of IKZF1 function in B cell precursor acute lymphoblastic leukemia (BCP-ALL) cell lines and patient-derived xenografts and compared cellular responses to various chemotherapeutic agents used in the treatment of BCP-ALL.

[Journal of Experimental & Clinical Cancer Research] Scientists provide a systematic summary of the current findings concerning the roles of ferroptosis in the tumor microenvironment (TME) and how ferroptosis-mediated TME reprogramming impacts cancer therapeutic resistance and progression.

[Haematologica] The Children’s Oncology Group trial AALL15P1 tested the safety and tolerability of five days of azacitidine treatment immediately prior to the start of chemotherapy on day six, in four post-induction chemotherapy courses for infants with newly diagnosed KMT2A-rearranged acute lymphoblastic leukemia.